Imv Inc (NYSE:IMV) – Stock analysts at Dawson James issued their Q2 2018 earnings estimates for shares of IMV in a research note issued on Tuesday, June 19th. Dawson James analyst C. Werther expects that the company will post earnings of ($0.06) per share for the quarter. Dawson James also issued estimates for IMV’s Q3 2018 earnings at ($0.08) EPS, Q4 2018 earnings at ($0.03) EPS, FY2018 earnings at ($0.22) EPS, FY2019 earnings at ($0.04) EPS, FY2020 earnings at ($0.07) EPS, FY2021 earnings at $0.04 EPS and FY2022 earnings at $0.26 EPS.
Separately, National Bank Financial reaffirmed an “outperform market weight” rating on shares of IMV in a report on Monday, June 4th.
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.